UPDATE : Monday, September 7, 2020
상단여백
‘Multinational drugmakers hypocritical in cancer, orphan drug biz’
Multinational drugmakers are demanding Seoul’s quicker approval for insuran...
by Nam Doo-hyun  |  2018-05-23 15:06
라인
Obesity treatment Saxenda supplied to 10 general hospitals
Novo Nordisk Pharma Korea said it has expanded the sales of Saxenda (ingred...
by Nam Doo-hyun  |  2018-05-23 11:13
라인
Refusals of off-label drugs spiked last year
Government regulators’ refusals of off-label drugs surged last year. Off-la...
by Nam Doo-hyun  |  2018-05-17 15:23
라인
How China’s scrapping of tariffs will affect Korea’s drug exports?
Korean drug exporters are paying attention to how China’s exemption of impo...
by Nam Doo-hyun  |  2018-05-16 12:14
라인
Merck’s Erbitux extends RSA status
Merck Korea and the health authorities have renewed their risk-sharing agre...
by Nam Doo-hyun  |  2018-05-15 14:31
라인
Biotech shares weaken on KONEX, too
As biotech stocks on KOSPI and KOSDAQ have turned downward since mid-April,...
by Nam Doo-hyun  |  2018-05-15 14:02
라인
‘Breast cancer drug Faslodex needs insurance coverage’
AstraZeneca Korea’s breast cancer treatment Faslodex (ingredient: fulvestra...
by Nam Doo-hyun  |  2018-05-11 11:31
라인
Samsung BioLogics shares recover despite window dressing controversy
Biotech and pharmaceutical shares are bouncing back from recent massive sli...
by Nam Doo-hyun  |  2018-05-10 11:08
라인
Va-Q-Tec to up investment in Korean biopharmaceuticals
Germany’s logistics and packaging company Va-Q-Tec said it would significan...
by Nam Doo-hyun  |  2018-05-09 11:54
라인
Pharma, biotech shares tank amid Samsung BioLogics debacle
Pharmaceutical and biotech shares are suffering a massive blow from repercu...
by Nam Doo-hyun  |  2018-05-08 11:20
라인
How much cheaper will Keytruda be as first-line treatment?
The pharmaceutical industry is paying attention to how much the price of MS...
by Nam Doo-hyun  |  2018-05-03 14:51
라인
Will US oncology conference boost Korean biotech shares?
Whether the upcoming annual meeting of the American Society of Clinical Onc...
by Nam Doo-hyun  |  2018-04-27 16:29
라인
Guerbet Korea under fire for exploiting monopoly drug
Guerbet Korea, the supplier of contrast media Lipiodol, is being criticized...
by Nam Doo-hyun  |  2018-04-26 15:37
라인
GC Pharma has most patents among large drug suppliers
GC Pharma had the largest number of patents among top-ranking local drugmak...
by Nam Doo-hyun  |  2018-04-26 11:08
라인
Pharma shares on the rise since early this year
Pharmaceutical and biotech shares have recently suffered declines, but most...
by Nam Doo-hyun  |  2018-04-25 13:56
라인
3 Korean pipelines listed in 537 new drug candidates in US
Three Korean treatments were included in 537 innovative drug candidates for...
by Nam Doo-hyun  |  2018-04-24 11:21
라인
Insulin Toujeo beats Tresiba in patient number
Novo Nordisk Korea recently boasted that its insulin product Tresiba (ingre...
by Nam Doo-hyun  |  2018-04-23 16:01
라인
Korean units of GSK, Pfizer send highest dividends to parent firms
Korean units of GlaxoSmithKline (GSK) and Pfizer showed the highest propens...
by Nam Doo-hyun  |  2018-04-20 14:48
라인
Biotech stocks could be overpriced: analysts
Analysts are warning investors that biotech shares could be overpriced, as ...
by Nam Doo-hyun  |  2018-04-19 13:34
라인
AstraZeneca up, Novartis down in Q1 outpatient prescriptions
AstraZeneca Korea’s outpatient prescription drug sales expanded by 7 billio...
by Nam Doo-hyun  |  2018-04-18 14:58
-12345678910-
176 civic groups furious over government-doctors deal176 civic groups furious over government-doctors deal
여백
Most viewed
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top